Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for recurrent or metastatic cervical cancer
ChiCTR1800020116Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Dec 2018; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800020116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020116.